Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Ad-RTS-hIL-12: Phase I ongoing

    Intrexon Corp. (NYSE:XON), Germantown, Md. Ziopharm Oncology Inc. (NASDAQ:ZIOP), Boston, Mass. Product: Ad-RTS-hIL-12 (Ad-IL-12) (ZIN ATI-001) (formerly INXN-2001) Business: Cancer Molecular target: Interleukin-12 (IL-…

    Published on 7/25/2016
  • AEB1102: Phase I started

    Aeglea BioTherapeutics Inc. (NASDAQ:AGLE), Austin, Texas Product: AEB1102 Business: Cancer Molecular target: Arginase 1 (ARG1) Description: Pegylated human recombinant arginase 1 (ARG1) Indication: Treat relapsed or …

    Published on 7/25/2016
  • CDX-014: Phase I/II started

    Celldex Therapeutics Inc. (NASDAQ:CLDX), Needham, Mass. Product: CDX-014 (formerly CR014-vcMMAE) Business: Cancer Molecular target: Hepatitis A virus cellular receptor 1 (HAVCR1) (TIM1) Description: Antibody-drug …

    Published on 7/25/2016
  • GemRIS: Phase Ib started

    Taris Biomedical LLC, Lexington, Mass. Product: GemRIS, gemcitabine-releasing intravesical system (TAR-200) (formerly TD-210) Business: Cancer Molecular target: NA Description: Drug-device combination using the Taris …

    Published on 7/25/2016
  • Lefitolimod: Phase I started

    Mologen AG (Xetra:MGN), Berlin, Germany Product: Lefitolimod (MGN1703) Business: Cancer Molecular target: Toll-like receptor 9 (TLR9) Description: Toll-like receptor 9 (TLR9) agonist based on double Stem Loop …

    Published on 7/25/2016
  • Macitentan: Phase III started

    Actelion Ltd. (SIX:ATLN), Allschwil, Switzerland Product: Macitentan (Opsumit) (formerly Actelion-1, ACT-064992) Business: Cardiovascular Molecular target: Endothelin receptor Description: Tissue-targeting endothelin …

    Published on 7/25/2016
  • Montelukast VersaFilm: Phase I started

    IntelGenx Corp. (TSX-V:IGX; OTCQX:IGXT), Saint-Laurent, Quebec Product: Montelukast VersaFilm (INT0043) Business: Neurology Molecular target: Cysteinyl leukotriene receptor 1 (CysLT1) Description: Oral disintegrating …

    Published on 7/25/2016
  • NYX-2925: Phase I started

    Aptinyx Inc., Evanston, Ill. Product: NYX-2925 Business: Neurology Molecular target: NMDA receptor Description: Small molecule that acts as an NMDA receptor functional glycine-site partial agonist Indication: Treat …

    Published on 7/25/2016
  • SER-262: Phase Ib started

    Seres Therapeutics Inc. (NASDAQ:MCRB), Cambridge, Mass. Nestle S.A. (SIX:NESN), Vevey, Switzerland Product: SER-262 Business: Infectious Molecular target: NA Description: Synthetically derived microbiome consisting of …

    Published on 7/25/2016
  • Trabodenoson/latanoprost: Phase II started

    Inotek Pharmaceuticals Corp. (NASDAQ:ITEK), Lexington, Mass. Product: Trabodenoson/latanoprost Business: Ophthalmic Molecular target: Adenosine A1 receptor (ADORA1); Prostaglandin F (FP) receptor (PTGFR) Description: …

    Published on 7/25/2016
  • VXM01: Phase I started

    Vaximm AG, Basel, Switzerland Product: VXM01 Business: Cancer Molecular target: Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1) Description: Oral T cell immunotherapy based on the recombinant,…

    Published on 7/25/2016
  • XOMA 213: Phase II started

    Xoma Corp. (NASDAQ:XOMA), Berkeley, Calif. Product: XOMA 213 (formerly LFA102) Business: Endocrine/Metabolic Molecular target: Prolactin receptor (PRLR) Description: Human IgG1 kappa mAb against prolactin receptor (PRLR…

    Published on 7/25/2016
  • 19-28z CAR T cells: Phase II resumed

    Juno Therapeutics Inc. (NASDAQ:JUNO), Seattle, Wash. Product: 19-28z CAR T cells (JCAR015) Business: Cancer Molecular target: CD19 Description: Autologous T cells expressing the 19-28z chimeric antigen receptor (CAR) …

    Published on 7/18/2016
  • AIR DNase: Phase II started

    Protalix BioTherapeutics Inc. (NYSE-M:PLX; Tel Aviv:PLX), Carmiel, Israel Product: AIR DNase (PRX-110) Business: Pulmonary Molecular target: Deoxyribonuclease I (DNASE1) Description: Inhaled recombinant human …

    Published on 7/18/2016
  • ALN-HBV: Phase I/II started

    Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Cambridge, Mass. Product: ALN-HBV Business: Infectious Molecular target: NA Description: RNAi therapeutic targeting the HBV genome and uses Enhanced Stabilization Chemistry (…

    Published on 7/18/2016
  • Ameluz aminolevulinic acid: Phase III started

    Biofrontera AG (Xetra:B8F), Leverkusen, Germany Product: Ameluz aminolevulinic acid (BF-200 ALA) Business: Dermatology Molecular target: Not available Description: Photodynamic therapy (PDT) comprising nanoemulsion BF-…

    Published on 7/18/2016
  • AZD4635: Phase I started

    Sosei Group Corp. (Tokyo:4565), Tokyo, Japan AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: AZD4635, HTL1071 Business: Cancer Molecular target: Adenosine A2A receptor (ADORA2A) Description: Small molecule …

    Published on 7/18/2016
  • BGB-3111: Phase I started

    BeiGene Ltd. (NASDAQ:BGNE), Beijing, China Product: BGB-3111 Business: Cancer Molecular target: Brutons tyrosine kinase (Btk) Description: Selective oral Brutons tyrosine kinase (Btk) inhibitor Indication: Treat B cell …

    Published on 7/18/2016
  • BGB-3111: Phase I started

    BeiGene Ltd. (NASDAQ:BGNE), Beijing, China Product: BGB-3111 Business: Cancer Molecular target: Brutons tyrosine kinase (Btk) Description: Selective oral Brutons tyrosine kinase (Btk) inhibitor Indication: Treat B cell …

    Published on 7/18/2016
  • BGB-A317: Phase I started

    BeiGene Ltd. (NASDAQ:BGNE), Beijing, China Product: BGB-A317 Business: Cancer Molecular target: Programmed cell death 1 (PD-1) (PDCD1) (CD279) Description: Humanized IgG4 mAb against PD-1 Indication: Treat B cell …

    Published on 7/18/2016
  • Cavosonstat: Completed Phase II enrollment

    Nivalis Therapeutics Inc. (NASDAQ:NVLS), Boulder, Colo. Product: Cavosonstat (N91115) Business: Pulmonary Molecular target: Alcohol dehydrogenase 5 (ADH5) (GSNOR) Description: Oral alcohol dehydrogenase 5 (ADH5; GSNOR) …

    Published on 7/18/2016
  • CK-2127107: Phase II started

    Cytokinetics Inc. (NASDAQ:CYTK), South San Francisco, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: CK-2127107, CK-107 Business: Musculoskeletal Molecular target: Sarcomere Description: Fast skeletal …

    Published on 7/18/2016
  • Durvalumab: Phase I started

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Durvalumab (MEDI4736) Business: Cancer Molecular target: Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274) Description: Human IgG1 mAb targeting PD-L1 …

    Published on 7/18/2016
  • Faldaprevir: Phase IIa started

    Trek Therapeutics PBC, Cambridge, Mass. Boehringer Ingelheim GmbH, Ingelheim, Germany Product: Faldaprevir (BI 201335) Business: Infectious Molecular target: HCV NS3/4A protease complex Description: Oral HCV NS3/4A …

    Published on 7/18/2016
  • GSK3359609: Phase I started

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: GSK3359609 Business: Cancer Molecular target: Inducible T cell co-stimulator (ICOS) Description: Inducible T cell co-stimulator (ICOS) agonist antibody …

    Published on 7/18/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993